Novo Nordisk: EPS up 22% in 2024

(CercleFinance.com) - Novo Nordisk has announced a 22% increase in EPS to 22.
63 DKK (just over E3) for 2024, as well as a 25% increase in operating profit (+26% at constant exchange rates) to 128.3bn DKK.


At 290.4bn DKK, annual sales were also up 26% at CER (including +30% in North America and +19% internationally); reflecting the fact that more than 45 million people are now benefiting from its treatments, it said.

For 2025, the Danish pharmaceutical company - focused mainly on diabetes and obesity - anticipates growth at CER of 19% to 27% for its operating profit and 16% to 24% for its sales.

At the AGM on 27 March, the Board of Directors will propose a final dividend of 7.90 DKK per share, which, together with the interim dividend paid last August, will bring the total dividend for 2024 to 11.40 DKK per share, up 21%.


Copyright (c) 2025 CercleFinance.com. All rights reserved.